Header Ads

Ibadan College of Medicine Alumni Association (ICOMAA) worldwide holds the 2026 distinguished alumni lecture.

    The event started with the anthems and the introduction of distinguished attendees. The president of ICOMAA worldwide, Emeritus Prof Samuel Omokhodion, and his wife, the Provost Professor Temidayo Ogundiran, the dean, Professor Lawal, Professor Mrs. Falusi, and Prof. Mrs. Osinusi the guest lecturer's mother and mother-in-law respectively, Professor Mrs. Atinmo, Professor Lagunju, Professor Emmanuel Otolorin, a past ICOMAA president, and Professor Wuraola Shokunbi, a past ICOMAA president and the chairperson of the program today, among many others. The masters of ceremonies were Dr. Gbolahan Obajimi, Dr. Shehu-Tijani Shittu, and Dr. Omobolaji Iyun. The chaplain of the Chapel of Resurrection and many other venerable members from the Chapel of Resurrection, including the guest speaker's brother, Dr. Falusi, were present as well. The Vice President of ICOMAA, Professor Adanze Asinobi, and the 11th Provost of the College, Professor Olapade-Olaopa, were also present.

    The opening address was given by the president of ICOMAA worldwide, Emeritus Professor Samuel Omokhodion. He commended all the work ICOMAA had been doing so far. He mentioned that the guest lecturer for today would be the first female ICOMAA distinguished lecturer. The Provost and the Deputy Vice Chancellor, on behalf of the Vice Chancellor, gave their addresses as well. The chairperson, Professor Wuraola Shokunbi, in her address, commended the IMSG; she recognized the presence of the president, IMSG-UK, and Ireland. The citation of the guest lecturer was read afterwards by Dr. Omobolaji Iyun.

    She started her lecture titled Viruses Don't Wait: From Discovery to Global Impact, by acknowledging her mother and mother-in-law, her, brother, and her son, her dad watching remotely. She then spoke about her work: translating advances in science to medicines, the cycle from discovery to translation to development to access and real-world impact. She spoke about
A) the crystal ball problem; the difficulty in extrapolating results of animal experimentation to humans, 
B) Paul Ehrlich's magic bullet problem, and 
C) Dr. Osinusi's "better than Fela" problem, a play on "better than the Beatles", where new is not good enough and significant improvement over the former is vital.

    She spoke about the Hepatitis C story, from non-A-non-B hepatitis to interferon treatment and the advance to finite single-pill-a-day treatment through targeted antivirals. From cure to elimination, Egypt's status as the first WHO gold-tier country regarding HCV elimination and how it was achieved was used as an example of a good track record. Hepatitis B on the other hand, while a cure has not been achieved, remains poorly controlled despite the advances in disease control. The advances are failing to reach people.

    HIV was discussed next: advances in research inclusivity, advances in the science - particularly the molecule lenacapavir, which achieved zero transmission of HIV and viral load control with just two administrations a year - and advances in delivery, with the drugs reaching all the way to eSwatini in the same month it was approved in the US and later, Abuja in Nigeria, a few months after.

    Science at the speed of need then, became the talking point, at which point the COVID virus came into the conversation. She told her COVID story, from being told about the virus on December 29, 2019, to January 25, 2020, when she got a call requesting the use of Remdesivir for compassionate use. To date, after global approval for Remdesivir, it has been used to treat millions, with over 60% of that number in low and middle-income countries. This science had started decades before with the nucleoside that triggered lenacapavir research found in 2009. 

    She then discussed filoviruses and Ebola. The current Democratic Republic of Congo epidemic has at least 11,504 confirmed cases and 5,630 deaths. The Zaire species is the only one mildly treatable. The Marburg, Sudan, and Bundibugyo viruses have no vaccines or treatments. Some pressing research questions include 1) treatment post-infection, 2) treatment that is effective irrespective of disease stage, and 3) post-exposure prophylaxis possibly achieved (preclinically) with oral obeldesivir. The WHO Partners program and the Ebola Post Exposure Prophylaxis trials for obeldesivir have been major drivers of the transformation from science to clinical trials during the Ebola outbreak. She concluded by stating that science cannot be triggered or started by the outbreak. The science must predate the outbreak to be timely. Also, effectiveness can be exclusive to timeliness; the science must not be done in isolation. "We may contribute at different times, but it is what we all do that makes a difference," in the words of Dr. Anu Osinusi. She spoke of Nubia, the first survivor of congenital ebola virus as a reminder of why all this matters. In the end, the work remains vital for the purpose of changing lives. She closed by thanking her family, friends, colleagues, and former classmates from the 2000 set. 
From L-R: Dr. Omobolaji Iyun, Emeritus Professor Samuel Omokhodion, Dr. Anu Osinusi, Professor Lawal, Professor Shokunbi, and Professor Otolorin.

    An award was presented to Dr. Anu Osinusi in appreciation of her delivery of the lecture. Also, the 1998 class of alumni was recognized with the ICOMAA president's award for their investments specifically to honour their teachers through the West African College of Physicians in different faculties, spending over 46,000 dollars. They were represented by Professor Lagunju, a professor of Paediatrics. The third award was to the chairman of the occasion, Professor Wuraola Shokunbi.

    The closing remarks were given after. Professor Shokunbi commended and congratulated the guest lecturer. Group photographs were taken, and a vote of thanks was given. The event ended soon after with the anthems.

Salami Wisdom 

No comments

Theme images by Michael Elkan. Powered by Blogger.